NASDAQ · TMCI

Treace Medical Concepts, Inc.

$4.08 +$0.08 (+2.00%) 1D After hours

Key Metrics

$259.49M
Market cap
P/E · TTM
$207.32M
Revenue · TTM
−$61.04M
Net income
EPS · TTM $-0.97
Dividend yield
Free cash flow −$25.96M
Beta · 1Y 1.55
EBITDA · TTM −$46.68M
Gross margin 79.7%

The Story So Far

LAST 6 MONTHS PRIMARY SOURCES ONLY
  • Jul 16
    Money rotated out of high-beta cohorts market-wide.

    High-beta names lagged the blue-chips by 20.3 points over ten sessions around this date. Stocks in that cohort weren't falling alone — they fell together.

    RECEIPT: ROTATION GAUGE, LIVE
  • May 12
    The stock moved +18.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, May 12
  • Apr 10
    The stock moved +18.3% in a single session.

    Sessions this size usually pair with a chapter above or below — a filing, a headline, or the whole cohort moving together.

    RECEIPT: DAILY BAR, Apr 10
  • Mar 30
    From its Jan 30 high, the share price fell 48%.

    Peak close $2.32 on Jan 30; trough close $1.20 on Mar 30. The drawdown is the fact — the chapters around it are the context.

    RECEIPT: PRICE SERIES, PEAK-TO-TROUGH -48%

The story updates itself as events post · The wolf reports; you decide

Snapshot

Market cap$259.49M
Enterprise value$263.46M
Shares outstanding64.9M
52-wk range$1.17 – $7.78
Avg volume · 20D517.5K
Net cash −$3.97M
Book value / share$1.23
IndustrySurgical & Medical Instruments & Apparatus
ExchangeNASDAQ
About Treace Medical Concepts, Inc.
IPO dateApr 23, 2021
Employees450

Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities.

Wolf Grade COMING SOON

The wolf is in training. Composite grades vs sector — profitability, health, value, momentum — arrive with the percentile engine. Methodology will be public.

Valuation

P/E
P/S1.25
P/FCF
EV/EBITDA
EV/Sales1.27
Graham №

Profitability

Gross 79.7%
Operating -26.9%
Net -29.4%
FCF -12.5%
ROE / ROIC -64.2% · —

Financial Health

Current ratio3.58
Quick ratio2.53
Debt / equity0.72
Debt / EBITDA -1.20
Net cash −$3.97M
Working capital$88.98M

Cash Flow · TTM

Operating CF −$12.93M
Capex −$13.04M
Free cash flow −$25.96M
Buybacks
Dividends paid
Shareholder yield

Piotroski F-Score

2 / 9
Weak fundamentals · 2 of 9 signals passing

Altman Z-Score

0.1
Distress zone (< 1.81) · elevated risk

Graham Number vs Price

Requires positive earnings and book value
Fundamentals through 2026-03-31 · computed by TickerWolf from SEC filings